MRK Merck & Co., Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

MRK [NYSE]

Merck & Co., Inc.

Healthcare | Drug Manufacturers - General | USA

statements

Index	DJIA S&P500	P/E	20.76	EPS (ttm)	3.98	Insider Own	0.10%	Shs Outstand	2.53B	Perf Week	4.57%
Market Cap	205.09B	Forward P/E	13.47	EPS next Y	6.13	Insider Trans	-1.83%	Shs Float	2.52B	Perf Month	4.77%
Income	10.20B	PEG	3.06	EPS next Q	1.35	Inst Own	77.80%	Short Float	0.58%	Perf Quarter	7.39%
Sales	48.08B	P/S	4.27	EPS this Y	58.90%	Inst Trans	0.33%	Short Ratio	1.50	Perf Half Y	-5.50%
Book/sh	10.35	P/B	7.97	EPS next Y	14.46%	ROA	12.10%	Target Price	93.00	Perf Year	-2.28%
Cash/sh	2.99	P/C	27.60	EPS next 5Y	6.78%	ROE	38.10%	52W Range	65.25 - 92.64	Perf YTD	-9.25%
Dividend	2.44	P/FCF	65.55	EPS past 5Y	-1.10%	ROI	19.20%	52W High	-10.90%	Beta	0.49
Dividend %	2.96%	Quick Ratio	0.90	Sales past 5Y	2.10%	Gross Margin	72.20%	52W Low	26.50%	ATR	1.74
Employees	71000	Current Ratio	1.10	Sales Q/Q	11.50%	Oper. Margin	25.50%	RSI (14)	63.34	Volatility	2.11% 1.95%
Optionable	Yes	Debt/Eq	1.07	EPS Q/Q	10.30%	Profit Margin	21.10%	Rel Volume	1.03	Prev Close	80.24
Shortable	Yes	LT Debt/Eq	0.83	Earnings	Jul 31 BMO	Payout	58.30%	Avg Volume	9.79M	Price	82.54
Recom	2.00	SMA20	4.92%	SMA50	5.25%	SMA200	0.70%	Volume	10,109,864	Change	2.87%

Aug-03-20

Upgrade

Goldman

Neutral → Buy

$91 → $105

Jun-12-20

Downgrade

Wolfe Research

Outperform → Peer Perform

Feb-27-20

Initiated

Barclays

Overweight

$93

Jan-07-20

Initiated

RBC Capital Mkts

Sector Perform

$99

Oct-17-19

Resumed

BofA/Merrill

Neutral

$90

Aug-16-19

Initiated

SVB Leerink

Outperform

Jul-03-19

Initiated

Mizuho

Buy

$97

May-28-19

Initiated

Goldman

Neutral

May-13-19

Upgrade

Atlantic Equities

Neutral → Overweight

Oct-16-18

Reiterated

Citigroup

Buy

$70 → $79

Oct-09-18

Resumed

Guggenheim

Buy

Apr-23-18

Upgrade

Goldman

Neutral → Buy

Apr-17-18

Upgrade

Morgan Stanley

Equal-Weight → Overweight

Apr-05-18

Upgrade

Barclays

Equal Weight → Overweight

$62 → $64

Mar-12-18

Upgrade

Leerink Partners

Mkt Perform → Outperform

Feb-14-18

Reiterated

Leerink Partners

Mkt Perform

$67 → $66

Feb-07-18

Reiterated

Morgan Stanley

Equal-Weight

$60 → $63

Jan-16-18

Upgrade

SunTrust

Hold → Buy

Nov-28-17

Resumed

BofA/Merrill

Buy

$64

Nov-24-17

Reiterated

Deutsche Bank

Hold

$62 → $59

Aug-03-20 04:28PM	Dow Jones Gets Microsoft Boost, Nasdaq Hits New High In Broad Stock Market Rally Investor's Business Daily
04:25PM	Johnson & Johnson stock rises Monday, outperforms market MarketWatch
03:06PM	Dow Jones Jumps 250 Points, Led By Microsoft, Apple; 5 Software Stocks To Watch With Earnings Due Soon Investor's Business Daily
02:24PM	Microsoft, Apple Inc. share gains contribute to Dow's nearly 275-point rally MarketWatch
12:54PM	Company News for Aug 3, 2020 Zacks
12:22PM	The Vanguard Health Care Fund Cuts Eli Lilly, Merck & Co. GuruFocus.com
11:12AM	Dow's 200-point climb led by gains in shares of Microsoft, Merck MarketWatch
11:03AM	Goldman Sachs Upgrades Merck On Cancer, HIV, COVID-19 Pipeline Benzinga
10:47AM	Buy Merck for Its Unappreciated Pipeline, Says Goldman Barrons.com
09:45AM	Microsoft, Apple Inc. share gains contribute to Dow's 130-point jump MarketWatch
06:30AM	Merck Animal Health Completes Acquisition of Worldwide Rights to VECOXAN® Brand of Parasiticides for Ruminant Portfolio Business Wire
Aug-02-20 04:31PM	The Market Continues to Undervalue AbbVie GuruFocus.com
Aug-01-20 01:03AM	Merck & Co. (MRK) Q2 2020 Earnings Call Transcript Motley Fool
Jul-31-20 06:33PM	Merck to Begin Pivotal COVID-19 Antiviral Studies in September Motley Fool
06:04PM	Stocks Close Higher Friday After Big Tech Earnings GuruFocus.com
04:31PM	Merck Earnings Top; Dow Drug Giant Raises Guidance Investor's Business Daily
04:25PM	Johnson & Johnson stock falls Friday, underperforms market MarketWatch
01:05PM	Dow Jones Dives 300 Points Despite Big Apple Gain; Nasdaq Reverses Lower Investor's Business Daily
12:00PM	Merck's Q2 Sales Got Clobbered by COVID-19, but Still Beat Estimates Motley Fool
11:56AM	Merck (MRK) Beats on Q2 Earnings, Misses Sales, Ups View Zacks
11:52AM	Caterpillar sales fall in Q2, Merck raises 2020 outlook Yahoo Finance Video
11:47AM	U.S. pledges $2.1B to Sanofi and GSK for 100 million doses of its COVID-19 vaccine Yahoo Finance Video
11:41AM	Merck to move COVID-19 treatment into large trials, sees sales recovering this year Reuters
10:36AM	RPT-Large U.S. COVID-19 vaccine trials will exclude pregnant women for now Reuters
09:54AM	Merck Posts Second-Quarter Earnings Beat and Lifts Guidance TheStreet.com
09:10AM	Merck's Debt Overview Benzinga
09:04AM	Merck plans large trials of antiviral COVID-19 drug in September Reuters
08:45AM	US STOCKS-Pandemic boost for Big Tech set to drive Wall St higher Reuters
08:25AM	Merck (MRK) Q2 Earnings Beat Estimates Zacks
07:41AM	Investor Optimism Abounds Merck & Co., Inc. (NYSE:MRK) But Growth Is Lacking Simply Wall St.
07:00AM	Merck's stock rallies after profit and sales beats, raised outlook MarketWatch
07:00AM	Large U.S. COVID-19 vaccine trials will exclude pregnant women for now Reuters
06:58AM	Merck sees recovery by year end after better-than-feared second quarter Reuters
06:55AM	Merck quarterly sales fall 7.6% as pandemic cuts doctor visits Reuters
06:45AM	Merck Announces Second-Quarter 2020 Financial Results Business Wire
Jul-30-20 04:25PM	Johnson & Johnson stock outperforms market on strong trading day MarketWatch
01:04PM	Merck & Co's Earnings Outlook Benzinga
12:58PM	Day Ahead: 3 Things to Watch for July 31 Investing.com
06:45AM	Merck Announces Two US Regulatory Milestones for KEYTRUDA® (pembrolizumab) in Triple-Negative Breast Cancer (TNBC) Business Wire
03:33AM	How Much Will Coronavirus Hurt Merck's (MRK) Q2 Earnings? (Revised) Zacks
Jul-29-20 07:32AM	The Daily Biotech Pulse: Merck's Breakthrough Therapy Designation, Sonoma Surges On Sanitizer News, Sanofi-Glaxo And More Benzinga
06:45AM	FDA Grants Breakthrough Therapy Designation to Mercks Novel HIF-2 Inhibitor MK-6482 for Treatment of Certain Patients With Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma Business Wire
Jul-28-20 05:05PM	'I feel quite confident that we can execute this': Pfizer CSO on COVID-19 vaccine Yahoo Finance Video
04:36PM	Pfizer CEO Says Companies Should Make Profit On Covid-19 Vaccines Barrons.com
09:42AM	How Much Will Coronavirus Hurt Merck's (MRK) Q2 Earnings? Zacks
Jul-27-20 06:11PM	US Indexes Close Higher Monday After 2-Day Selloff GuruFocus.com
Jul-25-20 12:01PM	How Much Will Drugmakers Charge for Covid-19 Vaccines? Questions About Pricing Arise. Barrons.com
Jul-24-20 04:57PM	Trump signs executive order aimed at lowering drug prices Yahoo Finance Video
01:14PM	Dow falls 219 points on losses in Intel, Pfizer stocks MarketWatch
12:30PM	Earnings Preview: Merck (MRK) Q2 Earnings Expected to Decline Zacks
12:16PM	Vaccine checkup: Where pharmaceutical companies stand in the fight against COVID-19 Yahoo Finance Video
10:46AM	Dow's 75-point fall led by losses in Intel, Pfizer stocks MarketWatch
Jul-23-20 01:08PM	Coronavirus: Why your local hospital may also need stimulus checks Yahoo Finance
11:39AM	Cross-Sector: Market Data Highlights Moody's
Jul-22-20 02:06PM	U.S. to pay Pfizer, BioNTech $1.95B for 100M doses of COVID-19 vaccine Yahoo Finance Video
Jul-21-20 04:48PM	Democratic lawmakers signal concern about coronavirus vaccine pricing, speed of development MarketWatch
04:09PM	Lawmaker Presses Drugmakers on Covid-19 Vaccine Pricing Barrons.com
02:50PM	House panel holds hearing with COVID-19 vaccine makers Yahoo Finance Video
11:16AM	Vaccine Makers Tell Congress They Are Hopeful, but Challenges Remain Barrons.com
09:34AM	Coronavirus vaccine developers vow diversity in clinical trials Reuters
Jul-20-20 07:00AM	A Big Contrarian Investor Sold Walmart, Merck and Pfizer Stock. Heres What It Bought. Barrons.com
Jul-19-20 11:09AM	Vaccine manufacturers testify before Congress, earnings bonanza: What to know in the week ahead Yahoo Finance
Jul-17-20 11:34AM	Merck's NDA for Heart Failure Candidate Gets Priority Review Zacks
11:12AM	Analyst Sees 60% Upside for Nabriva (NBRV) Following Merck Deal TipRanks
06:30AM	5 Biopharma Stocks That Are Affordable And Growing Barrons.com
Jul-16-20 07:30PM	T Rowe Price Equity Income Fund's Top 5 Buys in the 2nd Quarter GuruFocus.com
12:05PM	Cross-Sector: Market Data Highlights Moody's
11:29AM	Pharma Companies Look to Blockbusters to Drive Sales GuruFocus.com
06:45AM	FDA Grants Priority Review to Mercks New Drug Application for Vericiguat Business Wire
Jul-15-20 04:38PM	Dow Jones Giant Merck Inks A New Deal In Lung Cancer And Shares Pop Investor's Business Daily
12:05PM	Dow's 83-point climb led by gains in Raytheon Technologies Corp., Coca-Cola shares MarketWatch
09:48AM	Markets open higher on COVID-19 vaccine hopes Yahoo Finance Video
09:10AM	Merck, Novocure Team Up On Lung Cancer Treatment; Trial Set For 2H20 SmarterAnalyst
09:00AM	Merck Is Now Pursuing Two Coronavirus Vaccines Is Merck Stock A Buy? Investor's Business Daily
Jul-14-20 04:44PM	CORRECTED-Merck CEO says raising COVID-19 vaccine hopes 'a grave disservice' -report Reuters
09:45AM	McDonald's, Dow Inc. share gains lead Dow's nearly 75-point climb MarketWatch
Jul-13-20 06:33PM	Roche Forecasted to Be Top Drug Seller in 2026 GuruFocus.com
Jul-10-20 10:21AM	Merck's Keytruda Gets Priority Review for Lymphoma Indication Zacks
Jul-09-20 04:30PM	Merck Animal Health Receives U.S. FDA Approval of BRAVECTO® (fluralaner) Monthly Chews Business Wire
02:10PM	Coronavirus update: Florida sees deadliest day yet as US cases spike, economy jitters grow Yahoo Finance
11:44AM	Coronavirus vaccine makers to testify before U.S. House committee Reuters
08:53AM	New $1 billion fund aims to steer antibiotic companies in tough market Reuters
08:45AM	New $1 billion fund aims to steer antibiotic companies in tough market Reuters
08:40AM	New $1 bln fund aims to steer antibiotic companies in tough market Reuters
08:13AM	Merck's Keytruda Combo Gets CRL for First-Line Liver Cancer Zacks
07:00AM	Prominent plaintiffs' firms sought government bailout to stay afloat Reuters
06:45AM	FDA Grants Priority Review to Mercks Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for Second-Line Treatment of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Business Wire
Jul-08-20 04:30PM	Merck Announces Appointment of Organon & Co. General Counsel Business Wire
01:21PM	Dow Inc., American Express share losses lead the way, but Dow flat MarketWatch
12:59PM	Coronavirus update: US cases spike above 3M as WHO withdrawal draws more critics Yahoo Finance
11:30AM	Where COVID-19 vaccine trials stand Yahoo Finance Video
11:29AM	Immunomedics: A Solid Cancer Research Play GuruFocus.com
07:38AM	Merck, Eisai to put experimental cancer combination in new clinical trial MarketWatch
07:01AM	FDA declines to approve Merck and Eisai's liver cancer combo therapy Reuters
06:55AM	LYNPARZA® (olaparib) Approved in the EU for Germline BRCA-mutated Metastatic Pancreatic Cancer Business Wire
06:45AM	Merck and Eisai Receive Complete Response Letter for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma Business Wire
02:24AM	AstraZeneca-Merck's Lynparza wins EU approval for pancreatic cancer Reuters
02:15AM	AstraZeneca-Merck Lynparza wins EU approval for pancreatic cancer Reuters
Jul-07-20 05:50PM	Merck (MRK) Stock Moves -1.08%: What You Should Know Zacks
06:00AM	U.S. government awards Novavax $1.6 billion for coronavirus vaccine Reuters

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents for cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. It provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, esophageal, thyroid, cervical, and brain cancers; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. In addition, the company offers drugs for hepatocellular and merkel cell carcinoma; antibiotic and anti-inflammatory drugs for infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticides for sea lice in salmon; and antibiotics and vaccines for fish. Further, it provides companion animal products; diabetes mellitus treatment and anthelmintic products for dogs and cats; products to treat fleas, ticks, mosquitoes, and sandflies; horse fertility management products for swine; and dog, cat, and horse vaccines. Additionally, the company offers services and solutions that focus on engagement, clinical, and health analytics. Merck & Co., Inc. has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Almac Discovery Ltd.; Skyhawk Therapeutics, Inc.; Ridgeback Biotherapeutics; Shanghai Junshi Biosciences Co., Ltd.; and FUJIFILM Corporation. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers; and physicians and physician distributors, veterinarians, and animal producers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gerberding Julie L.	EVP Strat Comm, GI Pub Policy	Jul 17	Option Exercise	0.00	18,111	0	62,862	Jul 20 04:53 PM
Gerberding Julie L.	EVP Strat Comm, GI Pub Policy	Jul 17	Sale	80.00	36,285	2,902,976	26,577	Jul 20 04:53 PM
BRUN LESLIE A	Director	May 07	Option Exercise	0.00	5,000	0	6,948	May 07 04:48 PM
WEEKS WENDELL P	Director	May 07	Option Exercise	0.00	5,000	0	5,100	May 07 04:50 PM
WEEKS WENDELL P	Director	May 07	Sale	76.02	5,000	380,104	100	May 07 04:50 PM
BRUN LESLIE A	Director	May 07	Sale	75.46	5,000	377,300	1,948	May 07 04:48 PM
Nally Michael	EVP, Chief Marketing Officer	May 05	Option Exercise	76.86	2,345	180,237	12,054	May 06 05:14 PM
Karachun Rita A	Sr. VP Fince-Global Controller	May 05	Option Exercise	76.86	3,283	252,331	29,401	May 06 05:15 PM
Fleming Michael	SVP Chief Ethics & Com Officer	May 05	Option Exercise	76.86	1,290	99,149	7,304	May 06 05:16 PM
Clyburn Frank	EVP, Chief Commercial Officer	May 05	Option Exercise	76.86	3,752	288,379	82,611	May 06 05:17 PM
Clyburn Frank	EVP, Chief Commercial Officer	May 04	Option Exercise	77.67	1,904	147,884	79,797	May 06 05:17 PM
Fleming Michael	SVP Chief Ethics & Com Officer	May 04	Option Exercise	77.67	692	53,748	6,252	May 06 05:16 PM
Karachun Rita A	Sr. VP Fince-Global Controller	May 04	Option Exercise	77.67	1,212	94,136	26,715	May 06 05:15 PM
Zachary Jennifer	EVP, General Counsel	May 04	Option Exercise	77.67	5,772	448,311	9,489	May 06 05:13 PM
Nally Michael	EVP, Chief Marketing Officer	May 04	Option Exercise	77.67	1,298	100,816	10,274	May 06 05:14 PM
Karachun Rita A	Sr. VP Fince-Global Controller	May 03	Option Exercise	77.67	875	67,961	25,934	May 05 04:48 PM
Fleming Michael	SVP Chief Ethics & Com Officer	May 03	Option Exercise	77.67	1,541	119,689	6,089	May 05 04:42 PM
Gerberding Julie L.	EVP Strat Comm, GI Pub Policy	Jan 13	Option Exercise	0.00	82,548	0	139,111	Jan 15 05:15 PM
Gerberding Julie L.	EVP Strat Comm, GI Pub Policy	Jan 13	Sale	89.34	102,073	9,118,865	37,038	Jan 15 05:15 PM
Nally Michael	EVP, Chief Marketing Officer	Oct 30	Option Exercise	0.00	2,287	0	6,196	Nov 01 05:07 PM
MIZELL STEVEN	EVP, Chief HR Officer	Oct 30	Option Exercise	0.00	4,574	0	4,574	Nov 01 05:07 PM
Clyburn Frank	EVP, Chief Commercial Officer	Oct 30	Option Exercise	0.00	2,287	0	73,032	Nov 01 05:06 PM
Scholefield James H	EVP,Chief Info&Digital Officer	Oct 30	Option Exercise	0.00	11,436	0	11,436	Nov 01 05:04 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Aug 09	Option Exercise	0.00	6,427	0	77,951	Aug 12 05:13 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Aug 09	Sale	85.09	6,427	546,850	71,524	Aug 12 05:13 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Aug 08	Option Exercise	0.00	31,699	0	103,223	Aug 12 05:13 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Aug 08	Sale	85.01	31,699	2,694,789	71,524	Aug 12 05:13 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience